Breo Ellipta Asthma –Drug Forecast and Market Analysis to 2023
Breo Ellipta (Asthma) – Forecast and Market Analysis to 2023: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on sales@marketoptimizer.org with Breo
Ellipta (Asthma) – Forecast and Market Analysis to 2023 in subject line and your contact details.
“Breo Ellipta(Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Breo Ellipta (or Relvar Ellipta in Europe) is an FDC of fluticasone furoate and vilanterol trifenatate for the maintenance treatment of asthma in patients who need both an ICS and a LABA. Breo is dosed via a new
DPI device, Ellipta. Breo’s pharmacodynamics allow for once-daily administration, and it is going to be the first FDC that allows for once-daily administration for the maintenance treatment of asthma. This is due to its ICS component, fluticasone furoate, which is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity that can be dosed once a day, thus improving patient compliance and treatment outcomes. Fluticasone furoate is also being developed by GSK as a stand-alone ICS therapy.
Complete report available
Ellipta (Asthma) – Forecast and Market Analysis to 2023 in subject line and your contact details.
“Breo Ellipta(Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Breo Ellipta (or Relvar Ellipta in Europe) is an FDC of fluticasone furoate and vilanterol trifenatate for the maintenance treatment of asthma in patients who need both an ICS and a LABA. Breo is dosed via a new
DPI device, Ellipta. Breo’s pharmacodynamics allow for once-daily administration, and it is going to be the first FDC that allows for once-daily administration for the maintenance treatment of asthma. This is due to its ICS component, fluticasone furoate, which is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity that can be dosed once a day, thus improving patient compliance and treatment outcomes. Fluticasone furoate is also being developed by GSK as a stand-alone ICS therapy.
Complete report available
Bibliography: 7.2 Abbreviations 7.3 Methodology 7.4 Forecasting Methodology 7.4.1 Diagnosed Asthma Patients 7.4.2 Percent Drug-Treated Patients Contact sales@marketoptimizer.org / Call +1 888 391 5441 for further information on “Breo Ellipta (Asthma) – Forecast and Market Analysis to 2023” report OR for any other market research and intelligence needs you may have for your business.